Skip to main content

Table 1 Results for primary and secondary outcomes

From: Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials

Outcomes All studies with extractable data
ORP (95% CI), P value, I2 (P value), number of studies
Primary outcomes
 Major adverse cardiovascular events (MACE) 0.71 (0.46 to 1.09), P = 0.120, I2 = 10% (P = 0.324), 81 studies
 Death 0.89 (0.59 to 1.33), P = 0.573, I2 = 0% (P = 0.704), 90 studies
Secondary outcomes
 Myocardial infarction or urgent revascularization procedure 0.56 (0.28 to 1.11), P = 0.096, I2 = 5% (P = 0.395), 78 studies
 Stroke 0.65 (0.20 to 2.19), P = 0.490, I2 = 0% (P = 0.486), 76 studies
 Cardiovascular death 0.82 (0.49 to 1.38), P = 0.457, I2 = 0% (P = 0.725), 82 studies
 New/worsening hypertension 0.54 (0.37 to 0.80), P = 0.002, I2 = 0% (P = 0.494), 71 studies
 New/worsening heart failure 0.94 (0.68 to 1.28), P = 0.670, I2 = 55% (P = 0.023), 75 studies
 Arrhythmias 0.94 (0.33 to 2.67), P = 0.909, I2 = 0% (P = 0.539), 71 studies
 Total cardiovascular events 0.66 (0.54 to 0.80), P < 0.001, I2 = 49% (P = 0.002), 81 studies; D-L: 0.60 (0.44 to 0.82), P = 0.001, I2 = 41% (P = 0.012)
 Serious cardiovascular events 0.64 (0.51 to 0.81), P < 0.001, I2 = 34% (P = 0.050), 81 studies; D-L: 0.64 (0.46 to 0.89), P = 0.008, I2 = 24% (P = 0.135)
 Serious adverse events 0.93 (0.76 to 1.14), P = 0.488, I2 = 11% (P = 0.270), 81 studies
  1. OR P Peto odds ratio, except when indicted otherwise, CI confidence interval, I2 statistic of heterogeneity (P value of Cochran’s Q test), D-L DerSimonian and Laird random effects odds ratio with zero-cell continuity correction